Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis

Simple item page
dc.contributor.authorBlanco, Alejandro
dc.contributor.authorMorales, Fernanda
dc.contributor.authorMarcelain, Katherine
dc.contributor.authorHarismendy, Olivier
dc.contributor.authorSjöberg, Marcela
dc.contributor.authorArmisén, Ricardo
dc.contributor.authorde Santiago, Pamela
dc.date.accessioned2021-01-15T15:26:28Z
dc.date.available2021-01-15T15:26:28Z
dc.date.issued2020
dc.descriptionCentro de Genética y Genómica - ICIMes
dc.description.abstractAims: Breast cancer is one of the leading causes of woman deaths worldwide, being a major public health problem. It has been reported that the expression of the RNA-editing enzyme Adenosine Deaminase Acting on RNAs 1 (ADAR1) is upregulated in breast cancer, predicting poor prognosis in patients. A few reports in literature examine ADAR1 and long non-coding RNAs (lncRNAs) interplay in cancer and suggest key roles in cancer-related pathways. This study aimed to investigate whether ADAR1 could alter the expression levels of lncRNAs and explore how those changes are related to breast cancer biology. Main methods: ADAR1 overexpression and knockdown studies were performed in breast cancer cell lines to analyze the effects over lncRNAs expression. Guilt-by-Association correlation analysis of the TCGA-BRCA cohort was performed to predict the function of the lncRNA LINC00944. Key findings: Here, we show that LINC00944 is responsive to ADAR1 up- and downregulation in breast cancer cells. We found that LINC00944 expression has a strong relationship with immune signaling pathways. Further assessment of the TCGA-BRCA cohort showed that LINC00944 expression was positively correlated to tumor-infiltrating T lymphocytes and pro-apoptotic markers. Moreover, we found that LINC00944 expression was correlated to the age at diagnosis, tumor size, and estrogen and progesterone receptor expression. Finally, we showed that the low expression of LINC00944 is correlated to poor prognosis in breast cancer patients. Significance: Our study provides further evidence of the effect of ADAR1 over lncRNA expression levels, and on the participation of LINC00944 in breast cancer, suggesting to further investigate its potential role as prognostic biomarker.es
dc.description.versionPublicado
dc.identifier.citationde Santiago PR, Blanco A, Morales F, Marcelain K, Harismendy O, Sjöberg Herrera M, Armisén R. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sci. 2021 Mar 1;268:118956. doi: 10.1016/j.lfs.2020.118956.es
dc.identifier.urihttps://doi.org/10.1016/j.lfs.2020.118956es
dc.identifier.urihttp://hdl.handle.net/11447/3724
dc.language.isoenes
dc.publisherElsevier Inc.es
dc.sourceLife Sciences
dc.subjectADAR1es
dc.subjectBioinformaticses
dc.subjectBreast canceres
dc.subjectCanceres
dc.subjectGuilt by association analysises
dc.subjectLINC00944es
dc.subjectPrognosises
dc.subjectTumor-infiltrating lymphocyteses
dc.subjectlncRNAses
dc.titleImmune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosises
dc.typeArticlees

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is_ Armisen R et al_Pub.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services